KENALOG Drug Patent Profile

Which patents cover Kenalog, and when can generic versions of Kenalog launch?

Kenalog is a drug marketed by Delcor Asset Corp, Sun Pharm Inds Inc, and Apothecon. and is included in nine NDAs.

The generic ingredient in KENALOG is triamcinolone acetonide. There is one drug master file entry for this compound. Eighty suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Kenalog

A generic version of KENALOG was approved as triamcinolone acetonide by SUN PHARMA CANADA on October 1^st, 1986.

Summary for KENALOG

US Patents:	0
Applicants:	3
NDAs:	9
Raw Ingredient (Bulk) Api Vendors:	76
Clinical Trials:	83
Patent Applications:	4,799
Drug Prices:	Drug price information for KENALOG
What excipients (inactive ingredients) are in KENALOG?	KENALOG excipients list
DailyMed Link:	KENALOG at DailyMed

See drug prices for KENALOG

See drug sales revenues for KENALOG

Recent Clinical Trials for KENALOG

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Virginia Commonwealth University	PHASE1
British University In Egypt	PHASE2
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	NA

See all KENALOG clinical trials

US Patents and Regulatory Information for KENALOG

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Delcor Asset Corp	KENALOG	triamcinolone acetonide	CREAM;TOPICAL	083943-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Sun Pharm Inds Inc	KENALOG	triamcinolone acetonide	SPRAY;TOPICAL	012104-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Delcor Asset Corp	KENALOG	triamcinolone acetonide	LOTION;TOPICAL	084343-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Kenalog Market Dynamics, Patent Status, Competition, and Financial Trajectory

Last updated: October 8, 2026

Kenalog is a mature triamcinolone acetonide corticosteroid brand with limited standalone financial visibility. Its commercial position is driven by established clinical use, multiple dosage forms, physician familiarity, and demand for injectable corticosteroids. Long-expired core intellectual property and generic triamcinolone competition have shifted value away from exclusivity and toward manufacturing reliability, distribution, contracting, and formulation-specific regulatory approvals.

Kenalog revenue is not separately disclosed by its current or historical sponsor in public financial reports. A precise brand-level financial trajectory cannot be verified from company filings. The defensible conclusion is that Kenalog is a mature, low-growth brand exposed to price erosion, generic substitution, and a fragmented corticosteroid market.

What is Kenalog and which formulations are commercially important?

Kenalog is a trademark associated with triamcinolone acetonide products. The most commercially significant product is Kenalog-40 Injection, a 40 mg/mL intramuscular and intra-articular corticosteroid suspension. Other Kenalog-branded products have included lower-strength injectable products and topical or oral-mucosal formulations in certain markets.

Product category	Active ingredient	Typical strength or dosage form	Commercial role
Kenalog-40 Injection	Triamcinolone acetonide	40 mg/mL injectable suspension	Core branded injectable product
Kenalog-10 Injection	Triamcinolone acetonide	10 mg/mL injectable suspension	Lower-dose injectable segment
Topical Kenalog products	Triamcinolone acetonide	Cream, ointment, lotion, spray, or similar forms	Dermatology and inflammatory skin conditions
Oral paste products	Triamcinolone acetonide	Dental paste	Oral inflammatory lesions
Generic triamcinolone products	Triamcinolone acetonide	Injectable, topical, dental, or other formulations	Main source of price and share pressure

Kenalog products are corticosteroids, not biologics. They do not face biosimilar competition. The relevant competitive threat is generic substitution and competition from other corticosteroids, including methylprednisolone acetate, betamethasone, dexamethasone, and hydrocortisone products.

What is the FDA regulatory status of Kenalog?

Kenalog-40 Injection has long-standing U.S. regulatory status as an injectable triamcinolone acetonide suspension. The product label identifies triamcinolone acetonide as a glucocorticoid and describes systemic and local administration uses, including selected joint, tendon, bursal, and soft-tissue indications.[1]

The commercial distinction between a branded Kenalog product and generic triamcinolone acetonide depends on the specific dosage form, strength, route, labeling, and FDA approval pathway. A generic injectable suspension is not automatically substitutable for every other triamcinolone product merely because it has the same active ingredient.

Key regulatory issues include:

• Sterile injectable manufacturing.
• Suspension uniformity and particle-size control.
• Container-closure integrity.
• Preservative and excipient differences.
• Route-specific labeling.
• Demonstration of pharmaceutical equivalence for ANDA products.
• Institutional purchasing and formulary requirements.

FDA labeling also restricts administration routes. Kenalog-40 is not interchangeable with intravenous corticosteroid products merely because both contain triamcinolone or another glucocorticoid.[1]

What is the Orange Book status of Kenalog?

Kenalog's core product protection is not based on a current, commercially meaningful patent estate. The original product dates to the mid-20th century, placing foundational composition and formulation rights well beyond their enforceable patent terms.

The FDA Orange Book is the relevant source for current listed patents, exclusivity, and reference-product information. For mature products such as Kenalog-40, the principal commercial issue is generally whether a listed patent or regulatory exclusivity period remains active for the specific reference product, not whether the historical Kenalog brand once had patent protection.[2]

Protection category	Kenalog assessment
Core composition patent	Expired
Original product exclusivity	Expired
New chemical entity exclusivity	Not relevant to this mature product
Current biosimilar exclusivity	Not applicable
Formulation patents	Any surviving rights would require product-specific verification
Method-of-use patents	No known commercially material modern estate identified from the core public product record
Generic substitution risk	High
Paragraph IV exposure	Limited strategic importance because core protection is expired

No current patent should be assumed to block generic triamcinolone acetonide competition without reviewing the live Orange Book entry and the specific generic product application.

When did Kenalog lose exclusivity?

Kenalog lost meaningful market exclusivity decades ago. Its foundational patents and early regulatory exclusivity periods are long expired. The brand therefore competes in a post-exclusivity market in which generic manufacturers can offer triamcinolone acetonide products at lower prices.

The key commercial distinction is between:

1. The historical loss of exclusivity for triamcinolone acetonide as a molecule.
2. Product-specific approvals for injectable suspensions.
3. Any later patents covering a particular formulation, device, manufacturing process, or new use.

A later patent could theoretically protect a narrow product feature without restoring exclusivity for the active ingredient. Such protection would not prevent competition from older or differently formulated triamcinolone products.

How many patents cover Kenalog?

There is no clear basis for assigning Kenalog a meaningful active patent count without a current, product-specific patent search across U.S. and foreign databases. The original active ingredient and principal product architecture are mature and no longer protected by foundational patents.

The practical patent assessment is:

• Core active-ingredient protection: effectively zero commercial value.
• Core injectable product protection: expired or commercially exhausted.
• Current formulation protection: potentially relevant only if tied to a specific later-approved formulation.
• Manufacturing patents: may affect a particular competitor, but usually do not create broad Kenalog exclusivity.
• Method-of-use patents: unlikely to protect the full corticosteroid market.

Kenalog's patent strength is therefore weak. Its remaining commercial defenses are brand recognition, supply continuity, manufacturing quality, institutional relationships, and regulatory familiarity.

What generic entry risks exist for Kenalog?

Generic entry risk is high because triamcinolone acetonide has been available for many years and the market includes multiple alternative corticosteroid products.

Injectable competition

Injectable triamcinolone products compete on:

• Unit price.
• Availability of 10 mg/mL and 40 mg/mL strengths.
• Vial sizes.
• Preservative profile.
• Institutional contracts.
• Wholesaler availability.
• Shortage history.
• Physician familiarity.

Injectable suspensions can have more complex manufacturing and quality requirements than simple oral tablets. That complexity can limit the number of reliable suppliers, but it does not restore brand exclusivity.

Topical competition

Topical triamcinolone is highly commoditized. Creams, ointments, lotions, and similar products face strong generic pressure, private-label competition, and substitution among corticosteroid potency classes.

Clinical substitution

Kenalog also competes with non-triamcinolone corticosteroids. Physicians may select methylprednisolone acetate or betamethasone products based on route, duration of effect, local practice, payer policy, and supply.

What formulations are protected by Kenalog?

No broad, commercially significant formulation monopoly should be attributed to the Kenalog name alone. A branded formulation can remain commercially differentiated even where the molecule is generic, but differentiation does not equal patent protection.

The main technical barriers relate to injectable suspension performance:

• Stable dispersion of triamcinolone particles.
• Reproducible particle-size distribution.
• Sterility assurance.
• Sedimentation and redispersion behavior.
• Syringeability and vial withdrawal.
• Long-term stability.
• Consistent dose delivery.

These factors create regulatory and manufacturing barriers. They can delay or reduce the number of competitors, but they do not provide the same economic protection as an unexpired composition patent.

Which companies are challenging Kenalog?

Competition comes from generic pharmaceutical manufacturers rather than from a single branded challenger. The relevant competitive group includes companies that market triamcinolone acetonide injections, topical products, dental preparations, and related corticosteroids.

In the U.S., competitive pressure can arise from:

• ANDA-approved generic manufacturers.
• Authorized or private-label distributors.
• Hospital and specialty-pharmacy suppliers.
• Compounded-product facilities, where legally permitted.
• Alternative corticosteroid manufacturers.

The competitive landscape is fragmented. A single competitor is unlikely to replace all Kenalog demand because dosage forms, routes, procurement channels, and clinical uses differ.

What is the financial trajectory of Kenalog?

Kenalog's standalone revenue is not publicly reported in the financial statements of its sponsor. Bristol Myers Squibb's public reporting aggregates products into broader business categories and does not provide a separately identifiable Kenalog revenue line.[3]

A reasonable commercial trajectory is:

Period	Commercial condition	Financial implication
Early lifecycle	Protected or substantially differentiated product	Higher pricing power
Post-generic entry	Generic triamcinolone competition	Price and share erosion
Mature market	Brand retained for familiarity and supply reliability	Low growth, recurring but constrained revenue
Current market	Multiple generics and alternative steroids	Margin pressure and procurement-driven pricing
Long-term outlook	Stable clinical demand but limited exclusivity	Flat to declining nominal revenue unless supply disruption supports temporary gains

Unit demand can remain stable while brand revenue declines. Hospitals and clinics may continue purchasing Kenalog where physicians prefer the brand or where a generic supplier experiences a shortage. That supports residual demand but does not create durable pricing power.

The main financial variables are:

• Generic price discounts.
• Reimbursement and payer substitution.
• Institutional contracting.
• Product availability.
• Manufacturing costs.
• Sterile injectable shortages.
• Distributor inventory.
• Brand promotional spending.
• Product recalls or quality events.

Kenalog's economics are more consistent with a mature legacy pharmaceutical than with a growth asset.

What patent litigation and Paragraph IV challenges affect Kenalog?

No major current patent-litigation narrative is necessary to explain Kenalog's market position. The principal exclusivity barriers expired long ago, reducing the strategic importance of Paragraph IV litigation.

A Paragraph IV certification could still arise against a later-listed patent covering a particular product or indication. Such a challenge would concern the listed patent, not the expired triamcinolone acetonide molecule. Without an active, commercially material patent listing, Paragraph IV litigation is unlikely to be the principal determinant of generic entry.

The greater legal risks are product-specific:

• ANDA approval disputes.
• Patent disputes involving a later formulation.
• Trademark and trade-dress issues.
• False or misleading substitution claims.
• Manufacturing, sterility, or labeling enforcement.
• Contract and supply disputes.

How strong is the Kenalog patent estate?

Kenalog has a weak patent estate from an investment or licensing perspective. The asset has no apparent composition-of-matter moat, no biosimilar barrier, and no broad modern exclusivity framework.

Its residual defensibility is operational rather than legal:

Defense	Strength
Active-ingredient patent	Very weak or exhausted
Core product patent	Weak or expired
Brand recognition	Moderate
Physician familiarity	Moderate
Sterile manufacturing know-how	Moderate
Supply reliability	Potentially meaningful
Regulatory complexity	Moderate
Pricing power	Low
Switching costs	Low to moderate

The product may still have value in a portfolio of mature brands, particularly if the owner has efficient manufacturing and distribution. It is unlikely to justify a premium valuation based on patent exclusivity.

What licensing deals affect Kenalog?

No major publicly disclosed recent licensing transaction is required to explain Kenalog's current market economics. Historical rights, regional marketing arrangements, and product transfers may exist, but they are not separately visible in standard public financial filings.

Any transaction involving Kenalog should be valued primarily on:

• Net sales by formulation and territory.
• Gross-to-net deductions.
• Supply obligations.
• Manufacturing cost.
• Minimum purchase commitments.
• Recall liability.
• Existing generic competition.
• Trademark rights.
• Regulatory ownership.
• Geographic restrictions.

The trademark may have commercial value independent of patent rights, but that value depends on actual prescribing and procurement behavior.

How does Kenalog compare with competing corticosteroids?

Product or class	Main advantage	Main weakness versus Kenalog
Kenalog triamcinolone acetonide injection	Established brand and long clinical history	Low patent protection and generic competition
Generic triamcinolone injection	Lower price	Variable supplier availability and less brand familiarity
Methylprednisolone acetate injection	Broad clinical use and established alternatives	Direct therapeutic competition and similar procurement pressure
Betamethasone injection	Potency and clinical familiarity in selected uses	Different clinical profile and market positioning
Dexamethasone injection	Broad availability and multiple routes	Not a direct formulation substitute for every local use
Topical generic triamcinolone	Low price and broad availability	High commoditization
Compounded corticosteroid products	Customization in selected settings	Regulatory, quality, and supply limitations

Kenalog's strongest position is in familiar clinical applications where physicians value predictable supply and established product experience. Its weakest position is in price-sensitive procurement and generic-heavy topical markets.

What is the geographic coverage of Kenalog?

Kenalog is a global brand, but product availability, approved indications, manufacturers, and trademarks vary by jurisdiction. U.S. regulatory status does not establish approval or patent protection in Europe, Canada, Japan, or emerging markets.

Geographic risks include:

• Different national reference products.
• Local generic approval standards.
• Parallel trade.
• Regional trademark ownership.
• Country-specific reimbursement.
• Local manufacturing requirements.
• Import and sterile-product supply constraints.

The United States remains the most relevant market for Orange Book and Paragraph IV analysis. International valuation requires country-level regulatory and patent review.

What generic launch scenarios should investors consider?

Base case

Kenalog remains commercially available with stable clinical demand and gradual price erosion. Generic triamcinolone products retain most price-sensitive volume, while Kenalog preserves a smaller branded segment.

Downside case

A generic supplier improves availability, institutional contracts shift to lower-cost products, or the branded product experiences a supply disruption. Revenue and gross margin decline faster.

Upside case

A shortage among generic injectable suppliers temporarily increases demand for Kenalog. The effect is likely episodic unless the brand secures durable supply advantages or favorable contracting.

Risk case

A quality event, recall, manufacturing interruption, or regulatory action affects the brand. For a mature product, a temporary supply interruption can cause outsized commercial damage because the product has limited pricing power to offset lost volume.

Key Takeaways

• Kenalog is a mature triamcinolone acetonide brand, not a protected growth product.
• Core composition and product exclusivity expired decades ago.
• Generic and therapeutic competition creates high substitution risk.
• Kenalog has no biosimilar risk because it is a small-molecule corticosteroid.
• Injectable suspension manufacturing creates technical barriers but does not restore broad patent exclusivity.
• Standalone Kenalog revenue is not separately disclosed in public sponsor filings.
• Financial performance is likely driven by volume retention, generic pricing, supply reliability, and institutional contracting.
• The patent estate is weak; residual value comes from brand recognition, regulatory history, and manufacturing execution.
• The most relevant commercial event is likely a supply, contracting, or generic-availability change rather than a patent litigation outcome.

FAQs about Kenalog market value and exclusivity

Is Kenalog still under patent protection?

The foundational triamcinolone acetonide and original Kenalog protections are long expired. Any current patent analysis would need to focus on a specific formulation, use, or product listing.

Is generic triamcinolone the same as Kenalog?

Generic triamcinolone may contain the same active ingredient, but the products must be compared by dosage form, strength, route, excipients, labeling, and FDA approval status.

Can Kenalog be substituted automatically?

Substitution depends on the specific product, state law, pharmacy rules, institutional policy, and whether the generic is pharmaceutically equivalent to the referenced product.

Does Kenalog have biosimilar competition?

No. Kenalog contains triamcinolone acetonide, a small-molecule corticosteroid. Its competition comes from generics and other corticosteroids.

Is Kenalog a high-growth pharmaceutical asset?

No. Kenalog is best characterized as a mature, low-growth or declining branded asset whose value depends on residual demand, supply reliability, and manufacturing economics rather than patent exclusivity.

References

1. U.S. Food and Drug Administration. (2024). Kenalog-40 injection: Triamcinolone acetonide injectable suspension prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition.
3. Bristol Myers Squibb. (2024). 2023 annual report. Bristol Myers Squibb Company.

DrugChatter Q&A for KENALOG

Kenalog cream generic?